Antithrombotic medication and incident open-angle glaucoma

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 7, 2012, Pages 3801-3805

  Marcus, Michael W ^a   Müskens, Rogier P H M ^a   Ramdas, Wishal D ^b   Wolfs, Roger C W ^b   de Jong, Paulus T V M ^b,c,d   Vingerling, Johannes R ^b   Hofman, Albert ^b   Stricker, Bruno H C ^b   Jansonius, Nomdo M ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; FOLLOW UP; GONIOSCOPY; HUMAN; INCIDENCE; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MYOPIA; OPEN ANGLE GLAUCOMA; PERIMETRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; VISUAL FIELD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; MIDDLE AGED; NETHERLANDS; RISK FACTOR;

AGED; ANTICOAGULANTS; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INCIDENCE; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; NETHERLANDS; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RISK FACTORS; VISUAL FIELD TESTS;

EID: 84865837663     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9604     Document Type: Article

References (22)

1. Burr JM, Mowatt G, Hernández R, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess. 2007;11:iii-iv, ix-x, 1-190.
2. Costa VP, Harris A, Stefánsson E, et al. The effects of antiglaucoma and systemic medications on ocular blood flow. Prog Retin Eye Res. 2003;22:769-805.
3. Netland PA, Feke GT, Konno S, et al. Optic nerve head circulation after topical calcium channel blocker. J Glaucoma. 1996;5:200-206.
4. Dalen JE, Hirsh J. Antithrombotic therapy: introduction. Chest. 1992;102:303S-304S.
5. Ritch R. Neuroprotection: is it already applicable to glaucoma therapy? Curr Opin Ophthalmol. 2000;2:78-84.
6. Bentham P, Gray R, Sellwood E, Hills R, Crome P, Raftery J. Aspirin in Alzheimer's disease (AD2000): a randomised openlabel trial. Lancet Neurol. 2008;7:41-49.
7. Richard E, Kuiper R, Dijkgraaf MG, Van Gool WA. Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial. J Am Geriatr Soc. 2009; 57:797-805.
8. Attarzadeth A, Hosseini H, Nowroozizadeth S. Therapeutic potentials of aspirin in glaucomatous optic neuropathy. Med Hypotheses. 2006;67:375-377.
9. Lindén C, Alm A. Acetylsalicylic acid does not reduce the intraocular pressure variation in ocular hypertension or glaucoma. Exp Eye Res. 2000;70:281-283.
10. Bell NP, Orengo-Nania S, Pietz K, et al. Aspirin use in advanced uncontrollable glaucoma. J Glaucoma. 2004;13:365-370.
11. De Castro DK, Punjabi OS, Bostrom OG, et al. Effect of statin drugs and aspirin on progression in open-angle glaucoma suspects using confocal scanning laser ophthalmoscopy. Clin Experiment Ophthalmol. 2007;35:506-513.
12. Hofman A, van Duijn CM, Franco OH, et al. The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol. 2011;26:657-686.
13. Czudowska MA, Ramdas WD, Wolfs RC, et al. Incidence of glaucomatous visual field loss: a ten-year follow-up from the Rotterdam study. Ophthalmology. 2010;117:1705-1712.
14. Dielemans I, Vingerling JR, Hofman A, et al. Reliability of intraocular pressure measurement with the Goldmann applanation tonometer in epidemiological studies. Graefes Arch Clin Exp Ophthalmol. 1994;232:141-144.
15. Skenduli-Bala E, de Voogd S, Wolfs RC, et al. Causes of incident visual field loss in a general elderly population: the Rotterdam study. Arch Ophthalmol. 2005;123:233-238.
16. Wolfs RC, Borger PH, Ramrattan RS, et al. Changing views on open-angle glaucoma: definitions and prevalences-the Rotterdam Study. Invest Ophthalmol Vis Sci. 2000;41:3309-3321.
17. Santas AJ, Bahler C, Peterson JA, et al. Effect of heparin II domain of fibronectin on aqueous outflow in cultured anterior segments of human eyes. Invest Ophthalmol Vis Sci. 2003;44: 4796-4804.
18. Gonzalez JM Jr, Faralli JA, Peters JM, et al. Effect of heparin II domain on actin cytoskeleton and adherens junctions in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2006;47:2924-2931.
19. Gonzalez JM Jr, Hu Y, Gabelt BT, et al. Identification of the active site in heparin II domain of fibronectin that increases outflow facility in cultures monkey anterior segments. Invest Ophthalmol Vis Sci. 2009;50:235-241.
20. Marcus MW, M̈uskens RPHM, Ramdas WD, et al. Cholesterollowering drugs and incident open-angle glaucoma: a population- based cohort study. PloS ONE. 2012;7:e29724. Available at: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0029724. Accessed January 7, 2012.
21. Ramdas WD, Wolfs RCW, Hofman A, et al. Lifestyle and risk of developing open-angle glaucoma: the Rotterdam study. Arch Ophthalmol. 2011;129:767-772.
22. Stricker BH, Stijnen T. Analysis of individual drug use as a timevarying determinant of exposure in prospective populationbased cohort studies. Eur J Epidemiol. 2010;25:245-251.